Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme

A method for treating a disorder selected from the group consisting of type 2 diabetes, obesity, elevated plasma triglycerides, metabolic syndrome, non-alcoholic steatohepatitis, and non-alcoholic fatty liver disease, said method comprising the step of administering to a subject in need thereof a pharmaceutical composition comprising a compound of formula (I),

• or a pharmaceutically acceptable salt thereof, wherein
• R1 is hydrogen or alkyl;
• R2 is hydrogen;
• R3 is cycloalkyl, aryl, heteroaryl, heterocycle, —(CRaRb)m—R4, —C(O)OR5, —C(R5)═N—O(Ry), —C(O)—R5, or —C(O)—N(R5)(R6);
• m is 1, 2, 3 or 4;
• Ra, at each occurrence, is independently hydrogen, halogen, alkyl, alkenyl, haloalkyl, —OR7a, —N(R8)(R9), —C(O)OR7b, —C(O)—R7b, —C(O)—N(R8)(R9), —(CRcRd)p—OR7a, —(CRcRd)p—N(R8)(R9), —(CRcRd)p—C(O)OR7b, —(CRcRd)p—C(O)—R7b, —(CRcRd)p—C(O)—N(R8)(R9), aryl, heteroaryl, cycloalkyl, or heterocycle;
• Rb, at each occurrence, is independently hydrogen, halogen, alkyl, alkenyl, haloalkyl, —C(O)OR7b, —C(O)—R7b, —C(O)—N(R8)(R9), —(CRcRd)p—OR7a, —(CRcRd)p—N(R8)(R9), —(CRcRd)p—C(O)OR7b, —(CRcRd)p—C(O)—R7b, —(CRcRd)p—C(O)—N(R8)(R9), aryl, heteroaryl, cycloalkyl, or heterocycle;
• optionally, Ra and Rb together is ═CH2;
• Rc and Rd, at each occurrence, are each independently hydrogen halogen, alkyl, or haloalkyl;
• Ry is hydrogen, alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, heterocycle, cycloalkylalkyl, arylalkyl, heteroarylalkyl, or heterocyclealkyl;
• R4 is hydrogen, alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, or heterocycle, provided that when R4 is hydrogen, alkyl or haloalkyl, then at least one Ra is —OR7a, —N(R8)(R9), —C(O)OR7b, —C(O)—R7b, —C(O)—N(R8) (R9), —(CRcRd)p—OR7a, —(CRcRd)p—N(R8)(R9), —(CRcRd)p—C(O)OR7b, —(CRcRd)p—C(O)—R7b, or —(CRcRd)p—C(O)—N(R8)(R9);
• or Ra and Rb together is ═CH2;
• R5, at each occurrence, is independently alkyl, haloalkyl cycloalkyl, aryl, heteroaryl, heterocycle, cycloalkylalkyl, arylalkyl, heteroarylalkyl, or heterocyclealkyl;
• wherein each of the cycloalkyl, aryl, heteroaryl, heterocycle, cycloalkyl moiety of the cycloalkylalkyl, aryl moiety of the arylalkyl, heteroaryl moiety of the heteroarylalkyl, and heterocycle moiety of the heterocyclealkyl, as represented by R3, Ra, Rb, R4, R5, and Ry, is independently unsubstituted or further substituted with 1, 2, 3, 4 or 5 substituents selected from the group consisting of alkyl, halogen, haloalkyl, oxo, —OR10, —S(R14), —S(O)2R15, —S(O)2N(R11)(R12), —N(R11)(R12), —C(O)OR10, —C(O)O(trialkylsilylalkyl), —C(O)N(R11)(R12), —(CReRf)q—OR10, —(CReRf)q—N(R11)(R12), —(CReRf)q—C(O)OR10, —(CReRf)q—C(O)N(R11)(R12), G1, and ═N—O(R10);
• R6, R9 and R12, at each occurrence, are each independently hydrogen, alkyl or haloalkyl;
• R7a, at each occurrence, is each independently hydrogen, alkyl, haloalkyl, —N═C(H)R13a, —(CRgRh)r—C(O)OR13, or G1;
• R7b and R10, at each occurrence, are each independently hydrogen, alkyl, haloalkyl, (CRgRh)r—C(O)OR13, or G1;
• R8 and R11, at each occurrence, are each independently hydrogen, alkyl, haloalkyl, —S(O)2—R13a, —S(O)2—N(R13)(R14), —C(O)OR13, —C(O)N(R13)(R14), or G1;
• p, q, and r, at each occurrence, are each independently 1, 2, 3, or 4;
• Re, Rf, Rg, and Rh, at each occurrence, are each independently hydrogen, halogen, alkyl, or haloalkyl;
• R14, at each occurrence, is independently hydrogen, alkyl or haloalkyl;
• R15, at each occurrence, is independently alkyl, haloalkyl, or G1;
• R13, at each occurrence, is independently hydrogen, alkyl, haloalkyl, or G1;
• R13a, at each occurrence, is independently alkyl, haloalkyl, or G1;
• and
• G1, at each occurrence, is independently aryl, heteroaryl, cycloalkyl, heterocycle, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocyclealkyl, wherein the aryl, heteroaryl, cycloalkyl, heterocycle, aryl moiety of the arylalkyl, heteroaryl moiety of the heteroarylalkyl, cycloalkyl moiety of the cycloalkylalkyl, and heterocycle moiety of the heterocyclealkyl, are each independently unsubstituted or further substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of alkyl, halogen, —CN, —NO2, —OH, —O(alkyl), —NH2, —N(H)(alkyl), —N(alkyl)2, —C(O)OH, —C(O)O(alkyl), —C(O)NH2, —C(O)N(H)(alkyl), —C(O)N(alkyl)2, haloalkyl, and alkyl substituted with one substituent selected from the group consisting of —CN, —NO2, —OH, —O(alkyl), —NH2, —N(H)(alkyl), —N(alkyl)2, —C(O)OH, —C(O)O(alkyl), —C(O)NH2, —C(O)N(H)(alkyl), and —C(O)N(alkyl)2,
• in combination with a pharmaceutically acceptable carrier.